Track Carmell Therapeutics Corporation Class A Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Carmell Therapeutics Corporation Class A Common Stock CTCX · Stock Open Carmell Therapeutics Corporation Class A Common Stock in new tab

0.1973 USD
Add to portfolio
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Carmell Therapeutics Corporation Class A Common Stock (CTCX)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Carmell Therapeutics Corporation Class A Common Stock Logo Carmell Therapeutics Corporation Class A Common Stock Analysis (CTCX)

United States Health Care Official Website Stock

Is Carmell Therapeutics Corporation Class A Common Stock a good investment? Carmell Therapeutics Corporation Class A Common Stock (CTCX) is currently trading at 0.1973 USD.

Investor FAQ

Does Carmell Therapeutics Corporation Class A Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Carmell Therapeutics Corporation Class A Common Stock?

Carmell Therapeutics Corporation Class A Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

Exchange Ticker
NMS (United States) CTCX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion